JP2023510332A5 - - Google Patents
Info
- Publication number
- JP2023510332A5 JP2023510332A5 JP2022542294A JP2022542294A JP2023510332A5 JP 2023510332 A5 JP2023510332 A5 JP 2023510332A5 JP 2022542294 A JP2022542294 A JP 2022542294A JP 2022542294 A JP2022542294 A JP 2022542294A JP 2023510332 A5 JP2023510332 A5 JP 2023510332A5
- Authority
- JP
- Japan
- Prior art keywords
- reducing
- metabolism
- agent
- methyl
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959514P | 2020-01-10 | 2020-01-10 | |
| US62/959,514 | 2020-01-10 | ||
| PCT/US2021/012447 WO2021142083A1 (en) | 2020-01-10 | 2021-01-07 | A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510332A JP2023510332A (ja) | 2023-03-13 |
| JP2023510332A5 true JP2023510332A5 (https=) | 2024-01-16 |
| JP7728264B2 JP7728264B2 (ja) | 2025-08-22 |
Family
ID=74418549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542294A Active JP7728264B2 (ja) | 2020-01-10 | 2021-01-07 | シトクロムｐ４５０の阻害剤を用いて３－（（メチルスルホニル）アミノ）－２－（（（４－フェニルシクロヘキシル）オキシ）メチル）ピペリジン－１－カルボン酸メチルまたはその塩の薬物動態を改善するまたは血漿中濃度を上昇させる方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12594269B2 (https=) |
| EP (1) | EP4087534A1 (https=) |
| JP (1) | JP7728264B2 (https=) |
| KR (1) | KR20220127245A (https=) |
| CN (1) | CN115226390B (https=) |
| AU (1) | AU2021205892B2 (https=) |
| BR (1) | BR112022013547A2 (https=) |
| CA (1) | CA3167050A1 (https=) |
| MX (1) | MX2022008392A (https=) |
| WO (1) | WO2021142083A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4065585T3 (fi) | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| AR130709A1 (es) | 2022-10-07 | 2025-01-08 | Kissei Pharmaceutical | Compuesto de ciclopentano |
| KR20250085056A (ko) | 2023-12-05 | 2025-06-12 | 안희태 | 국궁 과녁에서 영역 구분 센서의 구성 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ524104A (en) * | 2000-09-08 | 2004-12-24 | Pharmacia Italia S | Exemestane as chemopreventing agent |
| HK1224173A1 (zh) | 2013-03-14 | 2017-08-18 | Pharmacyclics Llc | 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合 |
| PL3411358T3 (pl) | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| CA3032813A1 (en) | 2016-08-04 | 2018-02-08 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
| BR112022004576A2 (pt) | 2019-09-13 | 2022-06-14 | Takeda Pharmaceuticals Co | Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica |
| CA3154321A1 (en) | 2019-09-13 | 2021-03-18 | Takeda Pharmaceutical Company Limited | Tak-925 for use in treating narcolepsy |
-
2021
- 2021-01-07 MX MX2022008392A patent/MX2022008392A/es unknown
- 2021-01-07 WO PCT/US2021/012447 patent/WO2021142083A1/en not_active Ceased
- 2021-01-07 CA CA3167050A patent/CA3167050A1/en active Pending
- 2021-01-07 US US17/791,302 patent/US12594269B2/en active Active
- 2021-01-07 EP EP21702564.2A patent/EP4087534A1/en active Pending
- 2021-01-07 AU AU2021205892A patent/AU2021205892B2/en active Active
- 2021-01-07 CN CN202180017795.5A patent/CN115226390B/zh active Active
- 2021-01-07 KR KR1020227023475A patent/KR20220127245A/ko active Pending
- 2021-01-07 JP JP2022542294A patent/JP7728264B2/ja active Active
- 2021-01-07 BR BR112022013547A patent/BR112022013547A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023510332A5 (https=) | ||
| US11207370B2 (en) | Peptidomimetics for the treatment of coronavirus and picornavirus infections | |
| Das et al. | A survey of the structures of US FDA approved combination drugs | |
| US10787502B2 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| JP2006516570A5 (https=) | ||
| Ghosh et al. | Drug delivery to the oral cavity: molecules to market | |
| JP4832045B2 (ja) | メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物 | |
| TW200916103A (en) | Therapeutic compositions and methods | |
| JP2009500443A5 (https=) | ||
| JP2022514089A5 (https=) | ||
| NZ594618A (en) | Transdermal pharmaceutical preparations | |
| JP2006504795A5 (https=) | ||
| JP2023522010A5 (https=) | ||
| WO2020171727A2 (en) | Mucoadhesive compositions and uses thereof | |
| JP2023541432A5 (https=) | ||
| JP2006508953A5 (https=) | ||
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| JP2019515909A5 (https=) | ||
| JP2016528240A (ja) | ドルテグラビル、エムトリシタビン及びテノホビルの医薬コンビネーションを有する医薬 | |
| JP2005508963A5 (https=) | ||
| TW201414508A (zh) | 含５－氯－ｎ－（｛（５ｓ）－２－側氧－３－［４－（３－側氧－４－嗎啉基）苯基］－１，３－□唑啶－５－基｝甲基）－２－噻吩甲醯胺之醫藥投遞型式 | |
| JP2010500284A5 (https=) | ||
| JP2004538319A5 (https=) | ||
| JP2023512025A5 (https=) | ||
| JP2006503095A5 (https=) |